Arena Pharmaceuticals, Inc. (ARNA)

[misanthrope]

Aside from the restructuring, which carries costs despite the fact it is likely a necessary move, there is the de-emphasis of Belviq in terms of use for smoking cessation, as well as for weight loss when combined with phen. So - flagship product suddenly not so attractive. Also - cutting production at Swiss facility.

Overall - this company needs these steps, but it clearly represents a short term hit, and I suppose shareholders are anticipating a slow recovery as new leadership is appointed and sort through the details. Just my two cents.